Immune response in COVID-19: what is next?
Abstract The coronavirus disease 2019 (COVID-19) has been a global pandemic for more
than 2 years and it still impacts our daily lifestyle and quality in unprecedented ways. A …
than 2 years and it still impacts our daily lifestyle and quality in unprecedented ways. A …
COVID-19-associated coagulopathy and disseminated intravascular coagulation
The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression
of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The …
of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The …
Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19
ATTACC, ACTIV-4a, and REMAP-CAP … - New England Journal …, 2021 - Mass Medical Soc
Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …
Patients with COVID-19: in the dark-NETs of neutrophils
SARS-CoV-2 infection poses a major threat to the lungs and multiple other organs,
occasionally causing death. Until effective vaccines are developed to curb the pandemic, it …
occasionally causing death. Until effective vaccines are developed to curb the pandemic, it …
Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research
B Bikdeli, MV Madhavan, A Gupta… - Thrombosis and …, 2020 - thieme-connect.com
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …
Pharmacology of heparin and related drugs: An update
J Hogwood, B Mulloy, R Lever, E Gray, CP Page - Pharmacological reviews, 2023 - ASPET
Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …
Haematological manifestations of COVID‐19: From cytopenia to coagulopathy
C Agbuduwe, S Basu - European journal of haematology, 2020 - Wiley Online Library
Emerging data from the management of patients with coronavirus disease 2019 (COVID‐19)
suggests multi‐systemic involvement, including the hemopoietic system. The …
suggests multi‐systemic involvement, including the hemopoietic system. The …
Variants in ACE2; potential influences on virus infection and COVID-19 severity
The third pandemic of coronavirus infection, called COVID-19 disease, was first detected in
November 2019th. Various determinants of disease progression such as age, sex, virus …
November 2019th. Various determinants of disease progression such as age, sex, virus …
Glycosaminoglycan-protein interactions and their roles in human disease
D Shi, A Sheng, L Chi - Frontiers in molecular biosciences, 2021 - frontiersin.org
Glycosaminoglycans (GAGs) are a family of linear and negatively charged polysaccharides
that exist ubiquitously on the human cell surface as well as in the extracellular matrix. GAGs …
that exist ubiquitously on the human cell surface as well as in the extracellular matrix. GAGs …